Travere Therapeutics, Inc.
TVTX
Rangering i aksjer
#3489
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies... Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
Aksjekurs
$52.43
Markedsverdi
$4.94B
Endring (1 dag)
3.83%
Endring (1 år)
87.97%
Land
US
Handel Travere Therapeutics, Inc. (TVTX)
Kategori
Healthcare
P/B-forhold for Travere Therapeutics, Inc. (TVTX)
P/B-forhold per October 2026 TTM: 203.07
Ifølge Travere Therapeutics, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 203.07. Ved slutten av 2023 hadde selskapet et P/B-forhold på 3.32.
P/B-historikk for Travere Therapeutics, Inc. fra 2009 til 2026
P/B-forhold ved hvert års slutt
| År | P/B-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 203.07 | 773.04% |
| 2024 | 23.26 | 599.63% |
| 2023 | 3.32 | -89.37% |
| 2022 | 31.29 | 409.01% |
| 2021 | 6.15 | 0.21% |
| 2020 | 6.13 | 125.69% |
| 2019 | 2.72 | -5.44% |
| 2018 | 2.87 | 3.15% |
| 2017 | 2.79 | 22.46% |
| 2016 | 2.28 | 5.44% |
| 2015 | 2.16 | -126.23% |
| 2014 | -8.23 | 51.69% |
| 2013 | -5.42 | 5,071.21% |
| 2012 | -0.10 | 0.00% |
| 2011 | 0.00 | 0.00% |
| 2010 | 0.00 | 0.00% |
| 2009 | 0.00 | 0.00% |
P/B-forhold for lignende selskaper eller konkurrenter
| Selskap | P/B-forhold | Forskjell i P/B-forhold | Land |
|---|---|---|---|
| 6.251 | -96.92% |
US
|
|
| 13.2547 | -93.47% |
US
|
|
| 4.208 | -97.93% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -96.96% |
NL
|
